Pfizer gets fresh cancer drug rejection from NICE
LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.
The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.
(Reporting by Ben Hirschler; Editing by David Cowell)
- Tweet this
- Share this
- Digg this
- Cameron shifts tack on constitutional shake-up to mollify Scots
- Nationalists push for Irish unity vote after 'inspiring' Scottish referendum
- More Ukrainian soldiers killed, Poroshenko defends peace plan
- India gets its first transgender TV news anchor - newspaper
- China shooters disqualified, reinstated, set world record